BofA raised the firm’s price target on Arrowhead (ARWR) to $81 from $62 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm’s CNS Therapeutics Conference.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Cautious Optimism for Arrowhead Pharmaceuticals Amid Competitor’s Positive Obesity Treatment Data
- Morgan Stanley sees positive readthrough to Arrowhead pipeline from Wave data
- Arrowhead doses first subjects in ARO-MAPT trial
- Arrowhead rises 9.7%
- Arrowhead receives Breakthrough Therapy designation for plozasiran